MA27626A1 - Nouveaux derives de 2-pyridinecarboxamide - Google Patents

Nouveaux derives de 2-pyridinecarboxamide

Info

Publication number
MA27626A1
MA27626A1 MA28455A MA28455A MA27626A1 MA 27626 A1 MA27626 A1 MA 27626A1 MA 28455 A MA28455 A MA 28455A MA 28455 A MA28455 A MA 28455A MA 27626 A1 MA27626 A1 MA 27626A1
Authority
MA
Morocco
Prior art keywords
atom
formula
elements
group
oxygen
Prior art date
Application number
MA28455A
Other languages
English (en)
Inventor
Teruyuki Nishimura
Jun-Ichi Eiki
Morihiro Mitsuya
Makoto Bamba
Fumiko Sakai
Hitomi Watanabe
Yasuhiro Sasaki
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of MA27626A1 publication Critical patent/MA27626A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un composé qui a un effet activateur de la glucokinase et est utile comme agent thérapeutique contre le diabète sucré, étant représenté par une formule (I): [dans laquelle X1 représente un atome d'azote, atome de soufre, atome d'oxygène ou ceux semblables; R1 représente un groupement aryle de 6 à 10 éléments, groupement hétéroaryle de 5 à 7 éléments ou ceux semblables; D représente un atome d'oxygène ou atome de soufre; R2 et R3 sont les mêmes ou différents, chacun représentant un atome d'hydrogène, groupement alkyle inférieur ou ceux semblables; une formule (II) représente un groupement hétéroaryle facultativement substitué de 5 à 7 éléments ou ceux semblables; une formule (III) représente un groupement monocyclique ou bicyclique] ou un sel pharmaceutiquement acceptable de celui-ci.
MA28455A 2003-02-13 2005-08-24 Nouveaux derives de 2-pyridinecarboxamide MA27626A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003034987 2003-02-13
JP2003342860 2003-10-01
JP2004014799 2004-01-22

Publications (1)

Publication Number Publication Date
MA27626A1 true MA27626A1 (fr) 2005-11-01

Family

ID=32995582

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28455A MA27626A1 (fr) 2003-02-13 2005-08-24 Nouveaux derives de 2-pyridinecarboxamide

Country Status (20)

Country Link
US (3) US7629362B2 (fr)
EP (1) EP1598349B1 (fr)
JP (1) JP4400563B2 (fr)
KR (1) KR20050101208A (fr)
AR (1) AR045414A1 (fr)
AT (1) ATE517887T1 (fr)
AU (2) AU2004220234C1 (fr)
BR (1) BRPI0407283A (fr)
CA (1) CA2515841C (fr)
EC (1) ECSP056016A (fr)
IL (1) IL169905A0 (fr)
MA (1) MA27626A1 (fr)
MX (1) MXPA05008619A (fr)
NO (1) NO20054224L (fr)
NZ (1) NZ540791A (fr)
PE (1) PE20050194A1 (fr)
TW (1) TWI336329B (fr)
UA (1) UA82867C2 (fr)
WO (1) WO2004081001A1 (fr)
ZA (1) ZA200504852B (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
MXPA05003559A (es) 2002-10-03 2005-06-03 Novartis Ag (tiazol-2-il)-amida o sulfonamida substituida como activadores de glicocinasa utiles en el tratamiento de diabetes de tipo 2.
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7629362B2 (en) 2003-02-13 2009-12-08 Banyu Pharmaceutical Co., Ltd. 2-pyridine carboxamide derivatives
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
US7728025B2 (en) * 2003-12-29 2010-06-01 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted benzimidazole derivative
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
JP2007524682A (ja) * 2004-02-12 2007-08-30 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５の調節物質としてのビピリジルアミド
KR20070006816A (ko) 2004-04-02 2007-01-11 노파르티스 아게 티아졸로피리딘 유도체, 이를 함유하는 제약 조성물 및글루코키나제 매개형 증상의 치료 방법
AU2005229416B2 (en) 2004-04-02 2009-03-26 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
JPWO2006038741A1 (ja) 2004-10-08 2008-05-15 萬有製薬株式会社 チオエーテル化合物の製造方法
AU2005301608B2 (en) 2004-11-02 2012-09-13 Msd K.K. Aryloxy-substituted benzimidazole derivatives
AU2006217677A1 (en) * 2005-02-25 2006-08-31 Takeda Pharmaceutical Company Limited Pyridyl acetic acid compounds
US7414060B2 (en) 2005-03-04 2008-08-19 Hoffmann-La Roche Inc. Pyridine-2-carboxyamide derivatives
NZ564608A (en) 2005-07-09 2009-09-25 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
WO2007019210A1 (fr) 2005-08-05 2007-02-15 Bristol-Myers Squibb Company Preparation de derives d'acide 2-amino-thiazole-5-carboxylique
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2624102A1 (fr) 2005-09-29 2007-04-12 Sanofi-Aventis Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
CA2623958C (fr) 2005-09-30 2013-05-28 Banyu Pharmaceutical Co., Ltd. Derive indole substitue en position 2 par un groupe heteroaryle
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
DE602006018496D1 (de) 2005-10-05 2011-01-05 Hoffmann La Roche Naphthyridin-derivate
ATE521608T1 (de) * 2005-11-01 2011-09-15 Array Biopharma Inc Glucokinaseaktivatoren
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
EP2543667B1 (fr) * 2006-03-24 2015-01-28 Array Biopharma, Inc. Procédé de préparation d'analogues de 2-aminopyridine en tant qu'activateurs de la glucokinase
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
MX2009000688A (es) 2006-07-24 2009-01-30 Hoffmann La Roche Pirazoles como activadores de glucocinasa.
AR063028A1 (es) * 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
ATE542818T1 (de) * 2006-10-11 2012-02-15 Amgen Inc Imidazo- und triazolopyridinverbindungen und verfahren zu deren anwendung
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
US8314247B2 (en) * 2007-01-10 2012-11-20 Mitsubishi Tanabe Pharma Corporation Hydrazone derivative
US8431713B2 (en) 2007-01-24 2013-04-30 Array Biopharma, Inc. 2-aminopyridine derivatives as glucokinase activators
WO2008116107A2 (fr) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Activateurs de glucokinase
CA2681695A1 (fr) * 2007-03-23 2008-10-02 Array Biopharma Inc. Analogues de la 2-aminopyridine comme activateurs de la glucokinase
JP2010138073A (ja) * 2007-03-30 2010-06-24 Taisho Pharmaceutical Co Ltd ピコリン酸アミド化合物
WO2008156174A1 (fr) 2007-06-21 2008-12-24 Taisho Pharmaceutical Co., Ltd. Composé de pyrazinamide
EP2020232A1 (fr) * 2007-08-03 2009-02-04 Zeltia, S.A. Dérives de N-(1-thiazolyl)-amide pour traiter l'obésité, le diabète et des maladies cardiovasculaires
UA101166C2 (ru) 2007-09-21 2013-03-11 Аррей Биофарма Инк. Производные пиридин-2-иламино-1,2,4-тиадиазола как активаторы глюкокиназы для лечения сахарного диабета
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2703996A1 (fr) 2007-11-06 2009-05-14 Astrazeneca Ab Certains derives de 2-pyrazinone et leur utilisation comme inhibiteurs d'elastase des neutrophiles
AU2008321959B2 (en) 2007-11-12 2014-02-13 Msd K.K. Heteroaryloxy quinazoline derivative
CA2707403A1 (fr) * 2007-12-25 2009-07-02 Banyu Pharmaceutical Co., Ltd. Derives de n-pyrazole-2-pyridinecarboxamide
WO2009083553A1 (fr) * 2007-12-31 2009-07-09 Rheoscience A/S Composés azines en tant qu'activateurs de glucokinase
KR20100117137A (ko) * 2008-02-27 2010-11-02 메르크 파텐트 게엠베하 당뇨병 치료를 위한 카르복사마이드-헤테로아릴유도체
JP5498025B2 (ja) * 2008-03-13 2014-05-21 公益財団法人相模中央化学研究所 新規なチアゾール誘導体固定化マトリックス、及びその製造方法
JP5455380B2 (ja) * 2008-03-12 2014-03-26 公益財団法人相模中央化学研究所 新規なチアゾール誘導体、及びその製造方法
WO2009113637A1 (fr) * 2008-03-12 2009-09-17 東ソー株式会社 Nouveau dérivé de thiazole, matrice ayant un dérivé de thiazole immobilisé sur celle-ci, procédé de fabrication du dérivé de thiazole et procédé de fabrication de la matrice
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
JP2012500181A (ja) 2008-08-15 2012-01-05 Ｍｓｄ株式会社 アセチルピロリジニルインドール誘導体
EP2328892B1 (fr) * 2008-08-29 2013-01-16 Msd K.K. Dérivé d'oxotétrahydrofurann-2-yl-benzimidazole
PE20110303A1 (es) 2008-09-11 2011-05-21 Pfizer Derivados de heteroaril acetamidas como activadores de glucoquinasa
US8759539B2 (en) 2008-11-17 2014-06-24 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
ES2427279T3 (es) 2009-03-11 2013-10-29 Pfizer Inc. Derivados de benzofuranilo usados como inhibidores de glucocinasa
US20110021570A1 (en) * 2009-07-23 2011-01-27 Nancy-Ellen Haynes Pyridone glucokinase activators
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
NZ598262A (en) 2009-08-17 2014-05-30 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
KR101737151B1 (ko) * 2009-12-04 2017-05-17 닛산 가가쿠 고교 가부시키 가이샤 2-피리돈 화합물
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
US20150057220A1 (en) 2012-04-16 2015-02-26 Kaneq Pharma Inc. Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
US9527838B2 (en) 2012-12-17 2016-12-27 Merck Sharp & Dohme Corp. 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment
EA201692155A1 (ru) 2014-05-13 2017-04-28 Мемориал Слоун-Кеттеринг Кэнсэ Сентр МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
WO2022146755A1 (fr) * 2020-12-29 2022-07-07 Merck Sharp & Dohme Corp. Composés pyridyle amido-substitués et leurs méthodes d'utilisation pour le traitement des virus de l'herpès
IL280384B (en) * 2021-01-25 2022-09-01 Ag Plenus Ltd Herbicidal compounds and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS56115784A (en) 1980-02-15 1981-09-11 Tanabe Seiyaku Co Ltd Novel pyridinecarboxamide derivative and its preparation
JPS5795984A (en) 1980-12-05 1982-06-15 Tanabe Seiyaku Co Ltd Pyridinecarboxamide derivative and its preparation
JPS58121215A (ja) 1982-01-14 1983-07-19 Tanabe Seiyaku Co Ltd 抗アレルギ−剤
CH680582A5 (fr) 1991-04-23 1992-09-30 Supermatic Kunststoff Ag
GB2277930A (en) 1993-05-11 1994-11-16 Shell Int Research Herbicidal picolinamide derivatives
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
GB9725298D0 (en) 1997-11-28 1998-01-28 Zeneca Ltd Insecticidal thiazole derivatives
JP2002047278A (ja) 2000-08-02 2002-02-12 Fuji Photo Film Co Ltd チオエーテル化合物の製造方法
JP4723059B2 (ja) 2000-08-03 2011-07-13 帝人化成株式会社 難燃性熱可塑性樹脂組成物
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
SE519859C2 (sv) 2001-08-17 2003-04-15 Novacast Ab Anordning för behandling av järnlegeringar i ett kärl
AU2002952839A0 (en) 2002-11-21 2002-12-05 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
US7629362B2 (en) 2003-02-13 2009-12-08 Banyu Pharmaceutical Co., Ltd. 2-pyridine carboxamide derivatives
MXPA05009059A (es) * 2003-02-26 2005-10-19 Banyu Pharma Co Ltd Derivados de heteroarilcarbamoilbenceno.
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
CA2554686A1 (fr) 2004-02-18 2005-09-01 Astrazeneca Ab Composes
BRPI0507746A (pt) 2004-02-18 2007-07-10 Astrazeneca Ab composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
JPWO2006038741A1 (ja) 2004-10-08 2008-05-15 萬有製薬株式会社 チオエーテル化合物の製造方法
AR063028A1 (es) * 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
AR068540A1 (es) 2007-09-28 2009-11-18 Merck & Co Inc Metodos de produccion de un derivado de pirazol-3-il-benzamida.

Also Published As

Publication number Publication date
AU2010200004B2 (en) 2012-07-19
EP1598349A1 (fr) 2005-11-23
IL169905A0 (en) 2007-07-04
US8344003B2 (en) 2013-01-01
ECSP056016A (es) 2006-01-27
US20130085156A1 (en) 2013-04-04
KR20050101208A (ko) 2005-10-20
WO2004081001A1 (fr) 2004-09-23
JPWO2004081001A1 (ja) 2006-06-08
MXPA05008619A (es) 2005-11-04
ATE517887T1 (de) 2011-08-15
NO20054224D0 (no) 2005-09-12
ZA200504852B (en) 2006-05-31
EP1598349B1 (fr) 2011-07-27
NO20054224L (no) 2005-11-10
UA82867C2 (en) 2008-05-26
HK1088602A1 (zh) 2006-11-10
US20100041660A1 (en) 2010-02-18
CA2515841C (fr) 2010-06-01
TW200510381A (en) 2005-03-16
AU2004220234B2 (en) 2009-11-26
AU2004220234C1 (en) 2013-01-17
EP1598349A4 (fr) 2008-12-31
AR045414A1 (es) 2005-10-26
PE20050194A1 (es) 2005-04-23
AU2004220234A1 (en) 2004-09-23
US20060258701A1 (en) 2006-11-16
NZ540791A (en) 2009-09-25
JP4400563B2 (ja) 2010-01-20
AU2010200004A1 (en) 2010-01-28
US7629362B2 (en) 2009-12-08
BRPI0407283A (pt) 2006-01-31
US8765789B2 (en) 2014-07-01
CA2515841A1 (fr) 2004-09-23
TWI336329B (en) 2011-01-21

Similar Documents

Publication Publication Date Title
BRPI0413232A (pt) novos compostos tendo atividade inibitória contra os trasnportadores dependentes de sódio
DK0612321T3 (da) Pyridopyridazinon- og pyridazinthionforbindelser med PDE IV inhiberende aktivitet
DE60236851D1 (en) Pyrimidinmatrixmetalloproteinaseinhibitoren
MA29773B1 (fr) Derives de 1-h-pyrrole substitues par un groupe 1-heterocyclysulfonyle, 2-aminomethyle, 5-(hetero) aryle en tant qu'inhibiteurs des secretions acides
MA28024A1 (fr) Derives de (thio) carbamoyl-cyclohexane utilises en tant qu'antagonistes des recepteurs d3/d2
HUP0004259A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények
MA29323B1 (fr) Composes de l'acide pyridylacetique
MA30813B1 (fr) Derives de 2-pyridinecarboxamide ayant un effet d'activation sur la gk.
EA200300763A1 (ru) Пиридиновые ингибиторы матриксных металлопротеиназ
EP1426366A4 (fr) Derive thiazolidine et son utilisation medicamenteuse
EP1259487B8 (fr) Derives de 2-amino-nicotinamide et leur utilisation comme inhibiteurs de tyrosine kinase du recepteur vegf
DE69514367D1 (de) Substituierte amidderivate
LU91210I2 (fr) Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER)
HUP0004529A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
MA30029B1 (fr) Derives spiro aza-substitue
MA30524B1 (fr) Agent de lutte antiparasite contenant un nouveau derive de pyridyl-methanamine ou un sel de celui-ci
MA29250B1 (fr) Cyclohexylamides servant d'antagonistes des recepteurs de dopamine d3, d2 et de 5ht1a
EA200601235A1 (ru) Производные тиазола
DE60103136D1 (de) Imidazol derivate als raf kinase inhibitoren
EA200401615A1 (ru) ИНГИБИТОРЫ АКТИВАЦИИ NF-kB
NZ330973A (en) Azolobenzazepine derivatives as neurologically active agents
WO2004004730A3 (fr) Composes pharmaceutiques
DE69731940D1 (de) Uracilderivate enthaltende krebsmetastasen inhibitoren
KR930012698A (ko) β-옥소-β-벤젠프로판티오아미드 유도체